Thus, tumor mutational burden (TMB), PD-L1, and other biomarkers have been used as indicators for predicting the effectiveness of immunotherapy (3, 4), which also played important roles in regulating the tumor microenvironment (TME) (5). Here, CD274 is linked to neoplasm.